Wednesday, April 24, 2024
4/24/2024
SUMMARY All stages of neoplastic disease, from its development to metastasis, are intertwined with cancer immune evasion. The epigenetic mechanisms involved in the regulation of the tumor immune landscape are intensely investigated as biomarkers or therapeutic targets. 3' untranslated regions (3'UTRs) dictate the post- transcriptional mRNA fate and are often targeted by regulatory molecules such as microRNAs (miRNAs) and RNA binding proteins (RBPs). Tumor cells have been shown to evade this tight regulation by mutating or truncating these regions. The first such identified events have shed light on somatic regulatory mechanisms that could potentially affect tumor immune evasion, response to immunotherapy, and patient management. However, the transcriptome-wide detection, validation, and functional characterization of 3'UTR somatic events and their effects on the tumor immune landscape are still pressing -yet unmet- needs. In this project we will deploy an in silico/experimental framework that combines massively parallel variant validation, spatial transcriptomics, and bioinformatic detection/functionalization technologies to characterize Pan-Cancer and transcriptome-wide 3'UTR somatic mutation/truncation events, as well as to assess their potential as immunoediting mechanisms, markers for patient stratification, and novel therapeutic targets. Aim 1: By efficiently integrating raw multi-omic datasets, we will identify somatic 3'UTR mutations and truncations in more than 10,000 cancer patients across 33 cancer types. We will prioritize all 3'UTR variants affecting gene expression in cis, delineating the 3'UTR-mediated regulatory landscape across cancer types. Aim 2: We will identify mutations and disrupted circuitry affecting cancer immunophenotypes and the tumor microenvironment. We will utilize extensive post-transcriptional data/experimental resources to uncover the regulators (miRNAs, RBPs) and mechanisms involved in such immunoediting events. Aim 3a: We will validate up to 20,000 somatic 3'UTR events using a massively parallel sequencing technology. Prioritized interactions will be investigated in vitro as well as using a biomimetic 3D device to characterize their effects on gene regulation and T-Cell killing, while patient samples will be investigated using spatial transcriptomics. Aim 3b) We will assess the translational potential of the leading 3'UTR events and genes as predictors of immunotherapy response using Deep Learning models, against an extensive cohort of >300 cancer patients treated with immune checkpoint inhibition. We are uniquely suited to perform this in-depth characterization, since our research team comprises leading post transcriptional regulation and immune-oncology researchers, while the relevant resources (in silico, experimental, samples) are already in place. We will perform the first Pan-Cancer and transcriptome-wide investigation of tumor immune evasion by 3'UTR somatic mutations and truncations. We will use an innovative in silico-experimental framework to identify 3'UTR events, miRNAs, and RBPs that can be used as markers for efficient patient stratification as well as novel immunotherapeutic targets.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
